<b>In reaction to strong earnings/guidance: </b>CUR +15%, SCLN +14.1%, OME +12.4%, SNTA +9.3%, TAHO +5.9%, ZOES +5%, JASO +4.7%, PLPM +3.9%, (thinly traded), CETV +3.8%, XNET +3.4%, MILL +3.3%, MYRG +2.5%, (following late move higher into the close), AMOT +2.3%, MW +2.2%, DG +2%, LCUT +1.7%, REV +1.7%, CLSN +1.7%, COF +1.4%, THM +1.4%, NMRX +1.3%, (thinly traded), EYES +0.9%, PLOW +0.9%, KIRK +0.8%, PWE +0.7%<br/><br/><b>M&A news:</b> NVMI +6.1% (to acquire ReVera for $46.5 mln in cash), UTX +2.9% (to explore strategic alternatives for its Sikorsky Aircraft Business)<br/><br/><b>Select financial related names showing strength:</b> C +3.4% (Fed approves C's capital plan), MS +3.4% (announces share repurchase of up to $3.1 bln; Increases quarterly dividend to $0.15 from $0.10), RF +3.1% (increased dividend to $0.06 from $0.05 following CCAR; may repurchase up to $875 mln in common stock), AXP +2.3% (plans to increase quarterly dividend by 12% to $0.29/share and receives authorization to buy back up to $6.6 billion of common shares through Q2 2016), STI +2.1% (increased quarterly dividend to $0.24 from $0.20 per share; announced increase in share buyback program), LYG +1.9%, BK +1.5% (announces $3.1 bln buyback; dividend remains unchanged at $0.17), HBAN +1.3% ( received no Federal Reserve objection regarding capital actions), SAN +1.2% (Fed fails SAN, DB return plans), BCS +1.2%, USB +1.1% (Federal Reserve did not object to the Company's plan), BAC +0.5% (authorizes a $4 billion common stock repurchase program and is maintaining the common stock dividend at the current rate of $0.05/share per quarter), FITB +0.5% ( receives no objection to capital plan) <br/><br/><b>Select metals/mining stocks trading higher:</b> RIO +2.4%, FCX +2.2%, BHP +1.9%, ABX +0.8%<br/><br/><b>Select oil/gas related names showing strength:</b> SDRL +3.4%, RDS.A +3%, STO +2.9%, BP +2.3%, RIG +1.9%, TOT +1.8%<br/><br/><b>Other news:</b> CUR +15% (announces top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis; study met primary safety endpoints), LL +3.9% (files slides for today's business update; issues guidance), CTP +3.3% (appointed Vice Chairman Sylvain Dhenin as CEO; co also reported earnings), AZN +2.9% (may be related SLXP/ENDP), LMOS +2.6% (announced the sale of an aggregate of 1.6 mln shares of its common stock on an underwritten basis by an investment fund affiliated with Quadrangle Capital Partners L.P.), VRX +2% (following afternoon weakness on confirmed ENDP bid for SLXP), SQM +1.6% (informs that it has not presented any request to avoid delivery of information to the Public Prosecutor), AUY +1.4% (announces signing of definitive agreement with government of Catamarca), CLF +1% (announces results to date of exchange offers for senior notes and extension of early tender date), DSPG +0.8% (nnounces that the Board has unanimously authorized it to enter into a pre-arranged stock repurchase plan pursuant to Rule 10b5-1 under which it may repurchase shares of its Common Stock in the aggregate amount of up to $10 mln), TRIL +0.7% (filed for $57.5 mln offering of common shares)<br/><br/><b>Analyst comments: </b>AMRN +15.5% (upgraded to Buy from Neutral at H.C. Wainwright), WIN +3% (upgraded to Buy from Neutral at Citigroup), GNC +2.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley), NCS +1.8% (upgraded to Buy from Neutral at Citigroup)<br/><br/><b>In reaction to disappointing earnings/guidance:</b> INGN -15.6%, TKAI -14.1%, BOX -12.7%, KKD -9.1%, SHAK -6.2%, CMTL -5.4%, CMTL -5.4%, RLYP -5.2%, QIWI -3.6%, XOMA -3.2%, RST -2.1%, IPAR -0.7%<br/><br/><b>M&A news: </b>ENDP -0.9% (following afternoon weakness on confirmed ENDP bid for SLXP)<br/><br/><b>Other news: </b>ACAD -22.3% (provides an update on the planned timing of its NUPLAZIDTM (pimavanserin) New Drug Application (NDA) submission; plans to submit its NUPLAZID NDA for the treatment of Parkinson's disease psychosis in the second half of 2015, had previously planned to submit the NDA in the first quarter of 2015; Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer), CYBR -5.8% (prices 4,000,000 ordinary shares at a price of $51.00 per share), TRGP -3.6% (commences public offering of common stock), PE -2.3% (filed for ~14.89 mln share common stock offering by selling shareholders), GNCA -2% (intends to offer and sell shares of its common stock in an underwritten public offering), CNX -1.7% (downgraded to Underperform from Neutral at BofA/Merrill), NBG -1.6% (still moving with uncertainty in Greece), EQM -1.6% (prices 8,250,000 common units representing limited partner interests at $76.00 per common unit), BTE -0.6% (entered into an agreement to sell 28.82 mln common shares at $17.35 per share to raise gross proceeds of ~$500 mln on a bought deal basis)<br/><br/><b>Analyst comments:</b> ALKS -2.7% (downgraded to Underweight from Equal-Weight at Morgan Stanley), BTU -2% (downgraded to Underperform from Neutral at BofA/Merrill), GRMN -2% (downgraded to Underperform from Mkt Perform at Raymond James), LOGI -1.7% (downgraded to Underweight from Neutral at JP Morgan), SC -1.6% (downgraded to Hold from Buy at Deutsche Bank), MSI -1.4% (downgraded to Underperform from Mkt Perform at Raymond James), MTH -1.3% (downgraded to Neutral from Buy at Citigroup), PLT -0.9% (downgraded to Neutral from Overweight at JP Morgan), VRA -0.9% (downgraded to Underperform from Market Perform at Cowen)<br/><br/>Allikas: Briefing.com